A multiplex PCR primer set for detecting gastrointestinal cancer-related gene mutations and its use
The detection of gastrointestinal cancer-related gene mutations through multiple PCR primers sets solves the problems of early diagnosis of gastrointestinal cancer and postoperative recurrence warning, simplifies the high-throughput sequencing process, and realizes effective auxiliary diagnosis and early warning of gastrointestinal cancer.
Patent Information
- Application Number
- CN202411223704.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-09-03
AI Technical Summary
The prior art is difficult to effectively conduct early diagnosis of gastrointestinal cancer and postoperative recurrence warning, and the library construction process of high-throughput sequencing is complicated and fails to meet medical needs.
A multiplex PCR primer set is provided for detecting gene variants such as APC, BRAF, CDH1, CTNNB1, KRAS, NRAS, PIK3CA and TP53. Combined with circulating tumor cell detection methods, it is established through amplification and sequencing library to identify gene variants to assist Diagnosis and early warning.
Genetic testing assists in the diagnosis of gastrointestinal cancer, provides early warning, simplifies the complex process of high-throughput sequencing, and has great clinical and economic significance.
Smart Images

Figure CN118726591B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of molecular diagnosis, and in particular to a multiplex PCR primer set for detecting gastrointestinal cancer-related gene mutations and uses thereof. Background Art
[0002] Gastrointestinal cancer is the most common type of malignant tumor in the world. Since the early symptoms of digestive tract tumors are mostly not obvious, the onset is often hidden. Most patients are already in the middle or late stages when they show obvious symptoms, and are often accompanied by lymph node metastasis, so the patient survival rate is low.
[0003] Circulating tumor cells are tumor cells that shed from the primary tumor or metastatic lesions and enter the peripheral blood circulation. Their presence is an important marker of tumor metastasis and recurrence, so the detection of circulating tumor cells is of great significance for the early diagnosis, treatment effect evaluation and prognosis of gastrointestinal cancer. Summary of the invention
[0004] In view of the above-mentioned shortcomings of the prior art, an object of the present invention is to provide a multiplex PCR primer set for detecting gastrointestinal cancer-related gene mutations and its use, so as to solve the problems in the prior art.
[0005] To achieve the above-mentioned purpose and other related purposes, the present invention provides a multiplex PCR primer set for detecting lung tumor-related gene mutations, wherein the multiplex PCR primer set is a primer set for detecting any of the following genes: APC gene, BRAF gene, CDH1 gene, CTNNB1 gene, KRAS gene, NRAS gene, PIK3CA gene or TP53 gene.
[0006] Preferably, the multiplex PCR primer set comprises a primer pair having nucleotide sequences as shown in SEQ ID No. 1-70.
[0007] The present invention also provides the use of the aforementioned multiplex PCR primer set in preparing a circulating tumor cell detection product.
[0008] The present invention also provides a detection kit for gastrointestinal cancer-related genes in circulating tumor cells, wherein the detection kit comprises the aforementioned multiplex PCR primer set.
[0009] The present invention also provides a method for detecting gastrointestinal cancer-related gene mutations in circulating tumor cells for non-disease diagnosis purposes, the detection method comprising one or more of the following steps:
[0010] 1) Lyse the sample to be tested and amplify the whole genome of the sample to be tested;
[0011] 2) amplifying specific genes in the whole genome in step 1) using the aforementioned multiplex PCR primer set or the aforementioned detection kit to establish a sequencing library;
[0012] 3) Sequencing is performed using the sequencing library in step 2) to obtain the nucleotide sequence of the specific gene in step 2), and determining whether there is a gene mutation in the circulating tumor cells based on the comparison result between the nucleotide sequence and the sequence information of the standard library.
[0013] As described above, the multiplex PCR primer set for detecting gastrointestinal cancer-related gene mutations of the present invention and its use have the following beneficial effects: by performing genetic testing on abnormal cells in the blood, the mutations contained in these cells are discovered, thereby assisting in the diagnosis of gastrointestinal cancer. It can also be used to provide early warning of recurrence for patients after gastrointestinal cancer surgery, which can fill the existing unmet medical needs to a certain extent, and at the same time simplify the complex process of traditional library construction for high-throughput sequencing, which has great clinical and economic significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 Shown is an electrophoresis diagram of amplification using the primer set for a single gene in the present invention. Among them, lane 5 is a 50-700 bp DNA Marker; the DNA templates used in lanes 1-4, 6-9 are the products of 10 liver cancer cell lines HepG2 cells after whole genome amplification; the primer set used in lane 1 is for the TP53 gene, the primer set used in lane 2 is for the PIK3CA gene, the primer set used in lane 3 is for the NRAS gene, the primer set used in lane 4 is for the KRAS gene, the primer set used in lane 6 is for the CDH1 gene, the primer set used in lane 7 is for the BRAF gene, the primer set used in lane 8 is for exon 9 of the APC gene, and the primer set used in lane 9 is for exon 15 of the APC gene.
[0015] Figure 2 The electrophoresis diagram is shown as an amplification using the primer set optimized for the KRAS gene in the present invention. Lane 1 is a 100-1500 bp DNA Marker; the DNA template used in lane 2 is the product of whole genome amplification of 10 liver cancer cell lines HepG2 cells, using the optimized primer set for the KRAS gene.
[0016] Figure 3 The electrophoresis diagram is shown as amplification using the primer set for a single gene in the present invention. Lane 1 is a 50-700 bp DNA marker; Lane 2 uses a DNA template that is a product of whole genome amplification of 10 liver cancer cell lines HepG2 cells, and the primer set used is for the CTNNB1 gene.
[0017] Figure 4The electrophoresis diagrams of the two candidate groups of primer sets in the present invention are shown. Lane 4 is a 50-700 bp DNA Marker; the DNA templates used in lanes 1-3, 5-7 are the products of whole genome amplification of 10 liver cancer cell lines HepG2 cells; lanes 1-3 use primers C, B, and A of option 2; and lanes 5-7 use primers C, B, and A of option 1.
[0018] Figure 5 Shown are the statistical results of genes frequently mutated in colorectal cancer.
[0019] Figure 6 Shown are the statistical results of genes with frequent mutations in gastric cancer. DETAILED DESCRIPTION
[0020] The present invention provides a multiplex PCR primer set for detecting gastrointestinal cancer-related gene mutations, wherein the multiplex PCR primer set is a primer set for detecting any of the following genes: APC gene, BRAF gene, CDH1 gene, CTNNB1 gene, KRAS gene, NRAS gene, PIK3CA gene or TP53 gene.
[0021] In some specific embodiments, the multiplex PCR primer set comprises a nucleotide sequence such as SEQ ID No. 1-2, SEQ ID No. 3-4, SEQ ID No. 5-6, SEQ ID No. 7-8, SEQ ID No. 9-10, SEQ ID No. 11-12, SEQ ID No. 13-14, SEQ ID No. 15-16, SEQ ID No. 17-18, SEQ ID No. 19-20, SEQ ID No. 21-22, SEQ ID No. 23-24, SEQ ID No. 25-26, SEQ ID No. 27-28, SEQ ID No. 29-30, SEQ ID No. 31-32, SEQ ID No. 33-34, SEQ ID No. 35-36, SEQ ID No. 37-38, SEQ ID No. 39-40, SEQ ID No. 41-42, SEQ ID No. 43-44, SEQ ID No. 45-46, SEQ ID No. 47-48, SEQ ID No. 49-50, SEQ ID No. 51-52, SEQ ID No. 53-54, SEQ ID No. 55-56, SEQ ID No. 57-58, SEQ ID No. 59-60, SEQ ID No. 61-62, SEQ ID No. 63-64, SEQ ID No. 65-66, SEQ ID No. 67-68, SEQ ID No. 69-70, SEQ ID No. Multiple of the primer pairs shown in SEQ ID No.47-48, SEQ ID No.49-50, SEQ ID No.51-52, SEQ ID No.53-54, SEQ ID No.55-56, SEQ ID No.57-58, SEQ ID No.59-60, SEQ ID No.61-62, SEQ ID No.63-64 SEQ ID No.65-66, SEQ ID No.67-68, SEQ ID No.69-70, SEQ ID No.71-72, SEQ ID No.73-74, SEQ ID No.75-76 or SEQ ID No.77-78. Specifically, the multiplex PCR primer set comprises nucleotide sequences such as SEQ ID No.39-46 or SEQ ID No.71-78, and primer pairs shown in SEQ ID No.47-50 and SEQ ID No.59-70, for simultaneously amplifying KRAS gene, NRAS gene and TP53 gene; and / or, primer pairs such as nucleotide sequences such as SEQ ID No.15-18, SEQ ID No.33-38, SEQID No.51-58 and SEQ ID No.9-10, for simultaneously amplifying BRAF gene, CTNNB1 gene, PIK3CA gene and exon 9 of APC gene; and / or, primer pairs such as nucleotide sequences such as SEQ ID No.1-8, SEQ ID No.11-14 and SEQ ID No.19-32, for simultaneously amplifying exon 9 of APC gene and CHD1 gene.More specifically, the multiplex PCR primer set comprises a primer pair whose nucleotide sequences are shown as SEQ ID No. 1-78.
[0022] In some specific embodiments, based on the reaction system for simultaneously amplifying exon 9 of the APC gene and the CHD1 gene, the working concentration of the primers for amplifying the CHD1 gene is 0.4-0.6 times the working concentration of the primers for amplifying exon 9 of the APC gene.
[0023] In some specific embodiments, the multiplex PCR primer set comprises a primer pair whose nucleotide sequences are shown as SEQ ID No. 1-70.
[0024] In some specific embodiments, the primer pair further comprises a linker sequence fragment having a nucleotide sequence as shown in SEQ ID No.79 or SEQ ID No.80.
[0025] In some specific embodiments, the multiplex PCR primer set further comprises a library construction primer, wherein the library construction primer comprises a nucleic acid molecule having a nucleotide sequence as shown in any one of SEQ ID No.81-92.
[0026] The present invention also provides the use of the aforementioned multiplex PCR primer set in preparing a circulating tumor cell detection product.
[0027] The present invention also provides a detection kit for gastrointestinal cancer-related genes in circulating tumor cells, wherein the circulating tumor cell detection kit comprises the aforementioned multiplex PCR primer set.
[0028] In some embodiments, the circulating tumor cell detection kit further comprises a PCR reaction reagent. Specifically, the PCR reaction reagent comprises one or more of a PCR buffer, a DNA polymerase, magnesium ions, calcium ions, dNTPs, a surfactant or a preservative.
[0029] In some specific embodiments, the PCR buffer may be a phosphate buffer. The phosphate buffer is used to provide stable enzymatic reaction conditions. The surfactant is used to solubilize and disperse the solute to promote the enzymatic reaction. The preservative is used to control the growth of microorganisms in the PCR reaction reagent.
[0030] The phosphate in the phosphate buffer is selected from potassium phosphate or sodium phosphate. The potassium phosphate and sodium phosphate are selected from any one or more of potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium phosphate, sodium dihydrogen phosphate and disodium hydrogen phosphate.
[0031] The surfactant is a substance containing both a hydrophilic group and a hydrophobic group to significantly reduce the surface tension of the target solution. The surfactant is selected from any one or more of stearic acid, sodium dodecylbenzene sulfonate, quaternary ammonium compounds, lecithin, amino acid type, betaine type, alkyl glucoside, fatty acid glyceride, fatty acid sorbitan or polysorbate.
[0032] The preservative can be self-produced or commercially available. Preferably, the preservative is any one or more of the commercial ProClin series preservatives ProClin150, 200, 300 or 5000. More preferably, the preservative is ProClin300.
[0033] The present invention also provides a method for detecting gastrointestinal cancer-related gene mutations in circulating tumor cells for non-disease diagnosis purposes, the detection method comprising one or more of the following steps:
[0034] 1) Lyse the sample to be tested and amplify the whole genome of the sample to be tested;
[0035] 2) amplifying specific genes in the whole genome in step 1) using the aforementioned multiplex PCR primer set or the aforementioned detection kit to establish a sequencing library;
[0036] 3) Sequencing is performed using the sequencing library in step 2) to obtain the nucleotide sequence of the specific gene in step 2), and determining whether there is a gene mutation in the circulating tumor cells based on the comparison result between the nucleotide sequence and the sequence information of the standard library.
[0037] In some specific embodiments, the amplification in step 1) is as follows: the lysed sample, PCR buffer, random hexamer primers, dNTPs and Phi29 enzyme are mixed and reacted at 25-35° C. for 12-20 h.
[0038] In some specific embodiments, the specific gene in step 2) comprises one or more of APC gene, BRAF gene, CDH1 gene, CTNNB1 gene, KRAS gene, NRAS gene, PIK3CA gene or TP53 gene.
[0039] In some embodiments, the amplification in step 2) comprises the following steps:
[0040] Place the prepared sample in a thermal cycler and set the temperature of the hot cover to 95-105°C. The reaction program is as follows: 90-105°C for 1-5 min, 90-100°C for 20-40 s, 50-70°C for 20-40 s, 65-75°C for 0.5-2 min as one cycle, for a total of 30-40 cycles, and finally 65-75°C for 1-10 min.
[0041] In some specific embodiments, the establishment of the sequencing library in step 2) comprises one or more of the following steps:
[0042] a. Synthesize primers shown in nucleotide sequences SEQ ID No.81-92.
[0043] b. For each sample, select any one primer from SEQ ID No.87-92 (P7) and any one primer from SEQ ID No.81-86 (P5) as the primer pair for library construction. The combination of primers for library construction of any two samples in the same batch cannot be the same.
[0044] c For each sample, prepare the following PCR reaction system: mix DNA polymerase and buffer, library construction primer P7, library construction primer P5 and the amplified product in step 2).
[0045] d. Place the prepared sample in a thermal cycler and set the temperature of the hot cover to 95-105°C. The reaction program is as follows: 90-105°C for 1-5 min, 90-100°C for 20-40 s, 50-70°C for 20-40 s, 65-75°C for 0.5-2 min as one cycle, for a total of 1-10 cycles, and finally 65-75°C for 1-10 min.
[0046] g. After the reaction in step d is completed, for each sample, purify the PCR product.
[0047] h. The purified product is an Illumina Nextera library structure, which can be sequenced on an Illumina high-throughput sequencing platform, such as Illumina Novaseq 6000, according to the normal process.
[0048] In some specific embodiments, the comparison of the nucleotide sequence in step 3) with the sequence information of the standard library is:
[0049] After obtaining the high-throughput sequencing data of the sample, we first used BBDuk to perform quality control on the data, deleting reads with library adapter contamination and trimming low sequencing quality. Then we used Bowtie 2 to align the remaining reads to the human GRCh38 reference genome, and then used Freebayes to find sites with a variation frequency > 3%. Finally, we used SnpEff and SnpSift to annotate the variation, including predicting the effect of the variation, the impact on protein production, and finding out whether there is information on the corresponding variation site in the NCBI Clinvar database.
[0050] Software packages and databases involved in data processing and analysis:
[0051] BBMap (BBDuk is part of BBMap) – Bushnell B. – sourceforge.net / projects / bbmap /
[0052] Bowtie 2 – LANGMEAD B, SALZBERG S L. Fast gapped-read alignment with Bowtie 2 [J]. Nat Methods, 2012, 9(4): 357-359.
[0053] Freebayes – Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:1207.3907 [q-bio.GN] 2012
[0054] SnpEff – CINGOLANI P, PLATTS A, WANG LE L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3 [J]. Fly (Austin) , 2012, 6(2): 80-92.
[0055] SnpSift – CINGOLANI P, PATEL V M, COON M, et al. Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift [J]. Front Genet , 2012, 3: 35.
[0056] Clinvar – LANDRUM M J, LEE J M, BENSON M, et al.ClinVar: improving access to variant interpretations and supporting evidence [J]. Nucleic Acids Res , 2018, 46(D1): D1062-d1067.
[0057] In the present invention, sites with a variation frequency >3%, a sequencing depth >1650, and more than 30 reads supporting the variation are considered to be variations in the sample cell genome.
[0058] For details, see: PETRACKOVA A, VASINEK M, SEDLARIKOVA L, et al. Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonaland Subclonal Mutations in Cancer Diagnostics [J]. Front Oncol , 2019, 9: 851.
[0059] In the present invention, the term "circulating tumor cells" or "CTCs (circulating tumor cells)" generally refers to tumor cells that are shed from primary tumors or metastatic sites and enter the peripheral blood circulation system spontaneously or even as a result of surgery.
[0060] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0061] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.
[0062] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
[0063] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the field of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields. These techniques are well described in the literature, see Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; these series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, Chromatin (PM Wassarman and AP Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 119, Chromatin Protocols (PB Becker, ed.) Humana Press, Totowa, 1999, etc.
[0064] The amplification reaction system in the embodiment of this application is as follows:
[0065] 1) Prepare primer sets 10× Mix 1, 2, 3 and 10× Index Mix according to Table 1:
[0066] Table 1 Primer set preparation system
[0067] Mix 1 Mix 2 Mix 3 NRAS-E2-F 4 BRAF-E11-F 4 APC-R876-F 4.2 NRAS-E2-R 4 BRAF-E11-R 4 APC-R876-R 4.2 NRAS-E3-F 4 BRAF-E15-F 4 APC-R1114-F 4.2 NRAS-E3-R 4 BRAF-E15-R 4 APC-R1114-R 4.2 KRAS-E2-F 4 PIK3CA-E2-F 3.2 APC-Q1309-F 4.2 KRAS-E2-R 4 PIK3CA-E2-R 3.2 APC-Q1309-R 4.2 KRAS-E3-F 4.4 PIK3CA-E5-F 4.2 APC-Q1367-F 3.6 KRAS-E3-R 4.4 PIK3CA-E5-R 4.2 APC-Q1367-R 3.6 KRAS-E4-F 4.4 PIK3CA-E10-F 4 APC-Q1450-F 3.6 KRAS-E4-R 4.4 PIK3CA-E10-R 4 APC-Q1450-R 3.6 KRAS-E5-F 4 PIK3CA-E21-F 3 APC-T1556-F 4.2 KRAS-E5-R 4 PIK3CA-E21-R 3 APC-T1556-R 4.2 TP53-E4-F 3.2 CTNNB1-E3-F 4 CDH1-E2-F 2 TP53-E4-R 3.2 CTNNB1-E3-R 4 CDH1-E2-R 2 TP53-E5-F 3 CTNNB1-E7-F 4 CDH1-E3-F 2 TP53-E5-R 3 CTNNB1-E7-R 4 CDH1-E3-R 2 TP53-E6-F 2.5 CTNNB1-E8-F 4 CDH1-E6-F 2 TP53-E6-R 2.5 CTNNB1-E8-R 4 CDH1-E6-R 2 TP53-E7-F 3 APC-E9-F 6 CDH1-E8-F 2 TP53-E7-R 3 APC-E9-R 6 CDH1-E8-R 2 TP53-E8-F 3.2 10 mM Tris-HCl pH 8.0 (sterile) 119.2 CDH1-E9-F 2 TP53-E8-R 3.2 CDH1-E9-R 2 TP53-E10-F 3 Total volume 200 CDH1-E12-F 2 TP53-E10-R 3 CDH1-E12-R 2 10 mM Tris-HCl pH 8.0(sterile) 114.6 CDH1-E13-F 2 CDH1-E13-R 2 Total volume 200 10 mM Tris-HCl pH8.0 (sterile) 124 The concentration of each primer was 100 μM Total volume 200
[0068] 2) For the same WGA product sample, configure the following three PCR reaction systems:
[0069] Table 2 PCR system of Mix1
[0070] Reagents Volume (μL) 2× KAPA HiFi HotStart ReadyMix 10 10× Mix 1 2 WGA Products ~ 150 ng PCR Grade Water Up to 8
[0071] Table 3 PCR system of Mix2
[0072] Reagents Volume (μL) 2× KAPA HiFi HotStart ReadyMix 10 10× Mix 2 2 WGA Products ~ 150 ng PCR Grade Water Up to 8
[0073] Table 4 PCR system of Mix3
[0074] Reagents Volume (μL) 2× KAPA HiFi HotStart ReadyMix 10 10× Mix 3 2 WGA Products ~ 150 ng PCR Grade Water Up to 8
[0075] 3) Run PCR as follows:
[0076] Table 5 PCR parameters
[0077] temperature Number of cycles time 95℃ 1 180 s 98℃ 35 20 s 62.5℃ 35 15 s 72℃ 35 15 s 72℃ 1 30 s 4℃ maintain
[0078] 4) Mix the products of the three reaction systems in step 2) in equal proportions.
[0079] 5) Configure the following PCR reaction system:
[0080] Table 6 Mixed product PCR reaction system
[0081] Reagents Volume (μL) 2× KAPA HiFi HotStart ReadyMix 10 Any 10× Index Mix 2 Step 4) The obtained mixed product 1 PCR Grade Water 7
[0082] 6) Run PCR as follows:
[0083] Table 7 Mixed product PCR parameters
[0084] temperature Number of cycles time 98℃ 1 45 s 98℃ 5 15 s 62℃ 5 30 s 72℃ 5 30 s 72℃ 1 60 s 4℃ maintain
[0085] 7) The obtained PCR product is purified by a commercial kit to become an Illumina library that can be sequenced.
[0086] Example 1 Identification of primer sensitivity in multiplex PCR
[0087] Determination of the gene tested:
[0088] The COSMIC database (the Catalogue Of Somatic Mutations In Cancer) contains somatic acquired mutations found in human cancers. After querying the COSMIC database, the top five genes with the most frequent mutations in colorectal cancer are KRAS, BRAF, TP53, APC, and PIK3CA (e.g. Figure 5 ), so these five genes and the more important oncogene NRAS were selected as part of the test. The most frequently mutated genes in gastric cancer are TP53, PIK3CA, LRP1B, APC, KRAS, CTNNB1 and ARID1A (such as Figure 6 ). However, the LRP1B and ARID1A genes are very large (LRP1B has 99 exons, encoding 4599 amino acids; ARID1A has 20 exons, encoding 2285 amino acids) and have no obvious mutation hotspots, making them unsuitable for amplicon detection. Therefore, CDH1, which has a smaller gene and mutation hotspots, was selected as part of the test.
[0089] In summary, a total of 8 genes were detected, namely APC, BRAF, CDH1, CTNNB1, KRAS, NRAS, PIK3CA and TP53.
[0090] After querying the COSMIC database, the mutation frequencies of these genes in other digestive tract tumors are shown in Table 8:
[0091] Table 8 Statistical results of gene mutation frequency in digestive tract tumors
[0092] APC BRAF CDH1 CTNNB1 KRAS NRAS PIK3CA TP53 Colorectal cancer 48% 12% 5% 32% 4% 14% 45% Small Intestine Cancer 22% 5% 9% 22% 9% 26% Pancreatic cancer 7% 52% 39% Cholangiocarcinoma 6% 6% 5% 18% 7% 31% Gastric cancer 10% 12% 6% 6% 11% 37% Esophageal cancer 8% 52% Liver cancer 22% 30%
[0093] It can be seen that the primer set not only covers the common mutated genes of gastric and intestinal cancers, but also covers other cancers related to the digestive system.
[0094] To test the sensitivity of the primers, 100 HepG2 liver cancer cell lines (simulating CTCs) were spiked into 4 mL of peripheral blood, and CTCs were enriched and 10 liver cancer cells were picked. The sample was lysed, and whole genome amplification, specific gene amplification and library construction were performed according to the above reaction system, and sequencing was performed. The data obtained by sequencing was aligned to the human reference genome GRCh38, and the number of reads aligned to each amplicon region was counted. The higher the reads on the alignment, the better the sensitivity of the corresponding primer.
[0095] The results are shown in the following table. The number of reads on all amplicon alignments is greater than 4000, indicating that all regions to be tested have been sequenced more than 2000 times, which is sufficient for subsequent variant discovery and analysis. This result shows that the sensitivity of the primer pair meets the downstream analysis requirements.
[0096] Table 9 Amplification results of primer pairs for target gene fragments
[0097] chromosome Starting position End position Exon name Number of reads in the alignment chr1 114713799 114713978 NRAS_E3 118953 chr1 114716049 114716177 NRAS_E2 165076 chr12 25215440 25215560 KRAS_E5 123046 chr12 25225613 25225773 KRAS_E4 33492 chr12 25227232 25227412 KRAS_E3 7257 chr12 25245273 25245384 KRAS_E2 37181 chr16 68738296 68738411 CDH1_E2 119273 chr16 68801669 68801893 CDH1_E3 75560 chr16 68810196 68810341 CDH1_E6 106435 chr16 68812134 68812163 CDH1_E8 54012 chr16 68813312 68813495 CDH1_E9 119019 chr16 68822000 68822225 CDH1_E12 65423 chr16 68823398 68823626 CDH1_E13 78330 chr17 7670608 7670715 TP53_E10 51199 chr17 7673700 7673837 TP53_E8 95338 chr17 7674180 7674290 TP53_E7 95060 chr17 7674858 7674971 TP53_E6 126490 chr17 7675052 7675236 TP53_E5 98176 chr17 7675993 7676205 TP53_E4 82271 chr3 41224525 41224753 CTNNB1_E3 127201 chr3 41227207 41227352 CTNNB1_E7 26814 chr3 41233340 41233444 CTNNB1_E8 106511 chr3 179199087 179199177 PIK3CA_E2 110791 chr3 179203640 179203789 PIK3CA_E5 160295 chr3 179218209 179218334 PIK3CA_E10 61110 chr3 179234241 179234443 PIK3CA_E21 124899 chr5 112792409 112792562 APC_E9 87443 chr5 112838071 112838368 APC_R876 20388 chr5 112838785 112839073 APC_R1114 4277 chr5 112839284 112839545 APC_Q1309 15535 chr5 112839547 112839821 APC_Q1367 64891 chr5 112839837 112840088 APC_Q1450 85267 chr5 112840211 112840509 APC_T1556 45030 chr7 140753274 140753393 BRAF_E15 91644 chr7 140781575 140781693 BRAF_E11 126392
[0098] Example 2 Identification of primer specificity in multiplex PCR
[0099] To test the specificity of the primers, the eight genes were subjected to multiplex PCR according to the above reaction system, and the template of the PCR reaction was the whole genome amplification product in the above sample. The obtained products were electrophoresed in a 2% GelRed-stained agarose gel to evaluate whether there were other non-specific bands in addition to the expected bands. The expected band lengths of each gene are shown in the following table:
[0100] Table 10 Expected length of amplified fragments
[0101] Gene and exon numbers Expected length of amplified product APC_E9 273 APC_R876 366 APC_R1114 357 APC_Q1309 343 APC_Q1367 320 APC_Q1450 330 APC_T1556 367 BRAF_Exon11 316 BRAF_Exon15 317 CDH1_Exon2 283 CDH1_Exon3 363 CDH1_Exon6 361 CDH1_Exon8 354 CDH1_Exon9 357 CDH1_Exon12 360 CDH1_Exon13 367 CTNNB1-Exon3 353 CTNNB1-Exon7 330 CTNNB1-Exon8 360 KRAS_Exon2 332 KRAS_Exon3 354 KRAS_Exon4 313 KRAS_Exon5 315 NRAS_Exon2 269 NRAS_Exon3 326 PIK3CA_Exon2 252 PIK3CA_Exon5 343 PIK3CA_Exon10 283 PIK3CA_Exon21 271 TP53_Exon5 332 TP53_Exon6 237 TP53_Exon7 359 TP53_Exon8 330
[0102] like Figure 1 , 2 As shown in the figure, the amplification products of all genes except KRAS gene showed expected bands, and there were no obvious nonspecific bands and primer dimers, indicating that the primers have high specificity. The amplification efficiency of KRAS gene is not high, and primer dimers exist at 100-150 bp, which needs to be further optimized.
[0103] The primer set sequence of the original KRAS gene (for ease of presentation, the adapter sequence is not listed):
[0104] Table 11 Primer set sequences for the initial KRAS gene
[0105] Primer Name Sequence KRAS-E2-F SEQ ID No.71 AAAAGGTACTGGTGGAGTATTTGAT KRAS-E2-R SEQ ID No.72 TCATGAAAATGGTCAGAGAAACC KRAS-E3-F SEQ ID No.73 ACTGTGTTTCTCCCTTCTCAGG KRAS-E3-R SEQ ID No.74 TGCATGGCATTAGCAAAGAC KRAS-E4-F SEQ ID No.75 AGTTGTGGACAGGTTTTGAAAGA KRAS-E4-R SEQ ID No.76 TTTCAGTGTTACTTACCTGTCTTGT KRAS-E5-F SEQ ID No.77 ACTCTTACCAATGCAACAGACTT KRAS-E5-R SEQ ID No.78 GTGGTTGCCACCTTGTTACC
[0106] After trial and error, it was found that replacing the KRAS-E2 primer pair with the KRAS-E5 primer pair can effectively eliminate primer dimers and obtain clear target bands, such as Figure 3 shown.
[0107] The optimized primer set sequence of KRAS gene (for the convenience of display, the adapter sequence is not listed):
[0108] Table 12 Optimized primer set sequences for KRAS gene
[0109] Primer Name Sequence KRAS-E2-F SEQ ID No.39 GGTACTGGTGGAGTATTTGATAGT KRAS-E2-R SEQ ID No.40 CTCATGAAAATGGTCAGAGAAACCT KRAS-E3-F SEQ ID No.41 ACTGTGTTTCTCCCTTCTCAGG KRAS-E3-R SEQ ID No.42 TGCATGGCATTAGCAAAGAC KRAS-E4-F SEQ ID No.43 AGTTGTGGACAGGTTTTGAAAGA KRAS-E4-R SEQ ID No.44 TTTCAGTGTTACTTACCTGTCTTGT KRAS-E5-F SEQ ID No.45 TTCTTGCACATGGCTTTCCCA KRAS-E5-R SEQ ID No.46 AAAGACATCTGCTTTCTGCCAAA
[0110] Example 3 Grouping of primers in multiplex PCR
[0111] First, the primers corresponding to the 8 genes to be tested (final primer concentration of 0.2 μM) were configured for multiplex PCR in one tube, and the sequencing data were aligned to the human reference genome GRCh38, and the number of reads in each amplicon region was counted, as shown in the following table:
[0112] Table 13 Results of simultaneous amplification of primers corresponding to 8 gene configurations
[0113] Chromosome Start Position End Position Exon Name Number of Aligned Reads chr1 114713799 114713978 NRAS_E3 74489 chr1 114716049 114716177 NRAS_E2 221045 chr12 25215440 25215560 KRAS_E5 95435 chr12 25225613 25225773 KRAS_E4 4832 chr12 25227232 25227412 KRAS_E3 2517 chr12 25245273 25245384 KRAS_E2 14108 chr17 7670608 7670715 TP53_E10 4272 chr17 7673700 7673837 TP53_E8 78 chr17 7674180 7674290 TP53_E7 134 chr17 7674858 7674971 TP53_E6 48 chr17 7675052 7675236 TP53_E5 840 chr17 7675993 7676205 TP53_E4 12 chr3 41224525 41224753 CTNNB1_E3 254402 chr3 41227207 41227352 CTNNB1_E7 53628 chr3 41233340 41233444 CTNNB1_E8 213022 chr3 179199087 179199177 PIK3CA_E2 10 chr3 179203640 179203789 PIK3CA_E5 51476 chr3 179218209 179218334 PIK3CA_E10 103801 chr3 179234241 179234443 PIK3CA_E21 134886 chr5 112792409 112792562 APC_E9 193311 chr5 112838071 112838368 APC_R876 128966 chr5 112838785 112839073 APC_R1114 111183 chr5 112839284 112839545 APC_Q1309 16657 chr5 112839547 112839821 APC_Q1367 17956 chr5 112839837 112840088 APC_Q1450 1619 chr5 112840211 112840509 APC_T1556 220615 chr7 140753274 140753393 BRAF_E15 628 chr7 140781575 140781693 BRAF_E11 1697
[0114] According to the recommendation of "Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics" [PMID: 31552176], the minimum coverage depth required for targeted NGS mutation analysis is 1,650, and the threshold is set to observe at least 30 reads of alternative alleles, which can detect low variant allele frequencies of ≥3%. It can be seen that the coverage depth on some detection areas does not meet the above requirements, so these primers need to be further grouped to improve the efficiency of amplification.
[0115] The eight genes to be tested were divided into three groups according to the number of exons to be detected.
[0116] Option 1: Group A includes KRAS, NRAS, and TP53; Group B includes BRAF, CTNNB1, PIK3CA, and APC exon 9; Group C includes APC exon 15 and CDH1;
[0117] Option 2: Group A includes KRAS, NRAS, and PIK3CA; Group B includes BRAF, CTNNB1, TP53, and APC exon 9; Group C includes APC exon 15 and CDH1.
[0118] The above selections can make the number of amplicons in each group roughly equal. Configure the corresponding primers (final primer concentration is 0.2 μM) for multiplex PCR, and the obtained PCR products are electrophoresed in 2% GelRed-stained agarose gel to evaluate whether there are other nonspecific bands besides the expected bands.
[0119] like Figure 4 As shown, the primer dimers in option 1 (located around 100 bp) are significantly less than those produced in option 2, so the primers in option 1 have less interference and more valid data will be obtained during sequencing.
[0120] The product obtained in option 1 is used to complete the subsequent library construction process according to the technical plan, and the sequenced data is aligned to the human reference genome GRCh38, and the number of reads in each amplicon region is counted, as shown in the following table:
[0121] Table 14 Results of primer amplification in selection 1
[0122] chromosome Starting position End position Exon name Number of reads in the alignment chr1 114713799 114713978 NRAS_E3 563264 chr1 114716049 114716177 NRAS_E2 856377 chr12 25215440 25215560 KRAS_E5 523965 chr12 25225613 25225773 KRAS_E4 140728 chr12 25227232 25227412 KRAS_E3 25424 chr12 25245273 25245384 KRAS_E2 156255 chr17 7670608 7670715 TP53_E10 234667 chr17 7673700 7673837 TP53_E8 424287 chr17 7674180 7674290 TP53_E7 396091 chr17 7674858 7674971 TP53_E6 625181 chr17 7675052 7675236 TP53_E5 446088 chr17 7675993 7676205 TP53_E4 370332 chr3 179199087 179199177 PIK3CA_E2 575610 chr3 179203640 179203789 PIK3CA_E5 675816 chr3 179218209 179218334 PIK3CA_E10 289397 chr3 179234241 179234443 PIK3CA_E21 636543 chr5 112792409 112792562 APC_E9 406177 chr5 112838071 112838368 APC_R876 2143 chr5 112838785 112839073 APC_R1114 674 chr5 112839284 112839545 APC_Q1309 1671 chr5 112839547 112839821 APC_Q1367 97457 chr5 112839837 112840088 APC_Q1450 198569 chr5 112840211 112840509 APC_T1556 10107 chr7 140753274 140753393 BRAF_E15 407386 chr7 140781575 140781693 BRAF_E11 553680
[0123] It was found that when the APC and CDH1 genes in group C were amplified simultaneously, the amplification efficiency of the APC gene was low. Consider reducing the primer concentration of the CDH1 gene by 50% and testing again. The number of reads in each amplicon region alignment was counted, as shown in the following table:
[0124] Table 15 Amplification results after optimizing primer concentration ratio
[0125] chromosome Starting position End position Exon name Number of reads in the alignment chr1 114713799 114713978 NRAS_E3 118953 chr1 114716049 114716177 NRAS_E2 165076 chr12 25215440 25215560 KRAS_E5 123046 chr12 25225613 25225773 KRAS_E4 33492 chr12 25227232 25227412 KRAS_E3 7257 chr12 25245273 25245384 KRAS_E2 37181 chr16 68738296 68738411 CDH1_E2 119273 chr16 68801669 68801893 CDH1_E3 75560 chr16 68810196 68810341 CDH1_E6 106435 chr16 68812134 68812163 CDH1_E8 54012 chr16 68813312 68813495 CDH1_E9 119019 chr16 68822000 68822225 CDH1_E12 65423 chr16 68823398 68823626 CDH1_E13 78330 chr17 7670608 7670715 TP53_E10 51199 chr17 7673700 7673837 TP53_E8 95338 chr17 7674180 7674290 TP53_E7 95060 chr17 7674858 7674971 TP53_E6 126490 chr17 7675052 7675236 TP53_E5 98176 chr17 7675993 7676205 TP53_E4 82271 chr3 179199087 179199177 PIK3CA_E2 110791 chr3 179203640 179203789 PIK3CA_E5 160295 chr3 179218209 179218334 PIK3CA_E10 61110 chr3 179234241 179234443 PIK3CA_E21 124899 chr5 112792409 112792562 APC_E9 87443 chr5 112838071 112838368 APC_R876 20388 chr5 112838785 112839073 APC_R1114 4277 chr5 112839284 112839545 APC_Q1309 15535 chr5 112839547 112839821 APC_Q1367 64891 chr5 112839837 112840088 APC_Q1450 85267 chr5 112840211 112840509 APC_T1556 45030 chr7 140753274 140753393 BRAF_E15 91644 chr7 140781575 140781693 BRAF_E11 126392
[0126] After reducing the concentration of CDH1 gene primers, the sequencing depth of each amplicon was greater than 2000, which could meet the detection requirements.
[0127] Example 4 Application of multiplex PCR primer set
[0128] 100 HepG2 liver cancer cells (simulated CTC) were added to 4 mL of peripheral blood, CTC was enriched, and 10 liver cancer cells were picked. The sample was lysed, whole genome amplified, specific gene amplified and library constructed, and sequenced according to the technical plan. The data obtained by sequencing was aligned to the human reference genome GRCH38, and the number of reads on the alignment of each amplicon region was counted. The following mutations were found in the sample:
[0129] Table 16 Amplification results of target fragments in liver cancer cells by multiple PCR primer sets
[0130] chromosome chromosomal locus Gene name Transcript Base changes Protein changes ClinVar ID Clinical significance chr1 114713908 NRAS NM_002524.5 c.182A>T p.Gln61Leu 375874 Not yet clear
[0131] The mutation is consistent with the mutation of NRAS gene in HepG2 cell line included in the depmap database.
[0132] 100 RKO colon cancer cells (simulated CTC) were added to 4 mL of peripheral blood, CTC was enriched, and 10 colon cancer cells were picked. The sample was lysed, whole genome amplified, specific gene amplified and library constructed, and sequenced according to the technical plan. The sequenced data was aligned to the human reference genome GRCH38, and the number of reads on each amplicon region alignment was counted. The following mutations were found in the sample:
[0133] Table 17 Amplification results of multiplex PCR primer sets for target fragments in colon cancer cells
[0134] chromosome chromosomal locus Gene name Transcript Base changes Protein changes ClinVar ID Clinical significance chr3 179234297 PIK3CA NM_006218.4 c.3140A>G p.His1047Arg 13652 Pathogenicity chr7 140753336 BRAF NM_004333.6 c.1799T>A p.Val600Glu 13961 Pathogenicity
[0135] The mutations were consistent with the mutations of PIK3CA and BRAF genes in the RKO cell line included in the depmap database. Therefore, the multiplex PCR primer set can detect the mutations contained in CTC cells.
[0136] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and the variations of the methods in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of the present invention.
Claims
1. A multiplex PCR primer set for detecting gastrointestinal cancer-related gene mutations, characterized in that: The multiplex PCR primer set is a primer set for detecting the following multiple genes: APC gene, BRAF gene, CDH1 gene, CTNNB1 gene, KRAS gene, NRAS gene, PIK3CA gene and TP53 gene; The multiplex PCR primer set comprises primer pairs whose nucleotide sequences are shown as SEQ ID No.1-70, wherein the primer pairs whose nucleotide sequences are shown as SEQ ID No.39-46, SEQ ID No.47-50 and SEQ ID No.59-70 are used to simultaneously amplify KRAS gene, NRAS gene and TP53 gene; the primer pairs whose nucleotide sequences are shown as SEQ ID No.15-18, SEQ ID No.33-38, SEQID No.51-58 and SEQ ID No.9-10 are used to simultaneously amplify BRAF gene, CTNNB1 gene, PIK3CA gene and exon 9 of APC gene; the primer pairs whose nucleotide sequences are shown as SEQ ID No.1-8, SEQ ID No.11-14 and SEQ ID No.19-32 are used to simultaneously amplify exon 9 of APC gene and CHD1 gene.
2. The multiplex PCR primer set according to claim 1, characterized in that: The primer pair further comprises a linker sequence fragment having a nucleotide sequence as shown in SEQ ID No.79 or SEQ ID No.
80.
3. The multiplex PCR primer set according to claim 1, characterized in that: Taking the reaction system for simultaneously amplifying exon 9 of the APC gene and the CHD1 gene as a benchmark, the working concentration of the primer for amplifying the CHD1 gene is 0.4-0.6 times the working concentration of the primer for amplifying exon 9 of the APC gene.
4. The multiplex PCR primer set according to claim 1, characterized in that: The multiplex PCR primer set comprises library construction primers, and the library construction primers comprise a nucleic acid molecule whose nucleotide sequence is shown in any one of SEQ ID No.81-92.
5. Use of the multiplex PCR primer set according to any one of claims 1 to 4 in preparing a circulating tumor cell detection product.
6. A detection kit for gastrointestinal cancer-related genes in circulating tumor cells, characterized in that: The detection kit comprises the multiplex PCR primer set according to any one of claims 1 to 4.
7. The detection kit according to claim 6, characterized in that The detection kit also contains PCR reaction reagents.
8. The detection kit according to claim 7, characterized in that The PCR reaction reagents include one or more of a PCR buffer, a DNA polymerase, magnesium ions, calcium ions, dNTPs, a surfactant or a preservative.
